Trimethoprim-sulfamethoxazole in the treatment of Stenotrophomonas maltophilia osteomyelitis [4]

Clinical Infectious Diseases

Volumn 40, Issue 10, 2005, Pages 1551-1552

  Landrum, Michael L ^a   Conger, Nicholas G ^a   Forgione, Michael A ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b KEESLER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COTRIMOXAZOLE; GATIFLOXACIN; LEVOFLOXACIN; TIMENTIN; VANCOMYCIN;

AGED; ASPIRATION; BACTERICIDAL ACTIVITY; CASE REPORT; CLINICAL FEATURE; DRUG ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLUOROSCOPY; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PRIORITY JOURNAL; SPONDYLITIS; STENOTROPHOMONAS MALTOPHILIA;

AGED; ANTI-INFECTIVE AGENTS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; OSTEOMYELITIS; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 18244370506     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429730     Document Type: Letter

References (9)

1. Trumbore D, Pontzer R, Levison ME, et al. Multicenter study of the clinical efficacy of imipenem/cilastatin for treatment of serious infections. Rev Infect Dis 1985; 7:S476-81.
2. Agger WA, Cogbill TH, Busch H Jr., Landercasper J, Callister SM. Wounds caused by corn-harvesting machines: an unusual source of infection due to gram-negative bacilli. Rev Infect Dis 1986; 8:927-31.
3. Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2000; 45:115-7.
4. Cohn ML, Waites KB. Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies. Antimicrob Agents Chemother 2001; 45:2126-8.
5. Valdezate S, Vindel A, Baquero F, Canton R. Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 1999; 18:908-11.
6. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000; 45:363-5.
7. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997; 25:1327-33.
8. Garrison MW, Anderson DE, Campbell DM, et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996; 40:2859-64.
9. Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996; 22:508-12.